Beneath the threshold of standard detection, a shadow form of hepatitis B quietly rewires the liver's most fundamental instructions for growth and restraint. Researchers in Beijing have now traced the precise molecular path by which five mutations in the virus's pre-S region overwhelm the cell's natural brakes, activating a signaling cascade that transforms regulated tissue into uncontrolled tumor. In mapping this hidden mechanism, they have also identified two existing drugs capable of interrupting it — a discovery that places precision medicine one step closer to a disease that has long refu
Occult Hepatitis B Mutations Fuel Liver Cancer Through Akt/mTOR Pathway
The virus hijacks the cell's growth machinery, making it forget how to say no
Mark
Why does occult hepatitis B slip past standard screening when regular hepatitis B doesn't?
Mimi
The virus exists in the liver but doesn't produce the surface antigens that typical tests look for. It's like a burglar who leaves no fingerprints—the house is being robbed, but the usual evidence isn't there.
Mark
And these five mutations you identified—are they new, or have they always been there?
Mimi
They emerge over time as the virus replicates inside the liver. The mutations aren't random; they seem to be selected because they make the virus better at hijacking the cell's growth machinery. It's evolution in real time, inside a person's body.
Mark
So the virus makes more of this LHBs protein, which then triggers the Akt/mTOR pathway. Why does that particular pathway matter so much?
Mimi
Because Akt/mTOR is one of the cell's master switches for growth and division. When you activate it, you're essentially telling the cell to stop listening to its own safety signals. The cell forgets how to say no to division.
Mark
The inhibitors worked in the lab. Why can't we just give them to patients now?
Mimi
Because a petri dish isn't a liver. In the lab, we control everything—the cells, the drug concentration, the time. In a human body, the drug has to reach the right cells, avoid damaging healthy tissue, and work against a virus that's actively replicating. We need to know the dose, the side effects, whether it actually stops cancer from developing.
Mark
What happens if these drugs don't work in humans?
Mimi
Then we've at least identified the mechanism clearly enough that other researchers can design different approaches—maybe combination therapies, or ways to boost the immune system to recognize and clear the infected cells. The map matters even if this particular route doesn't work.
Mark
How many people are we talking about here?
Mimi
Occult hepatitis B is a global problem, but exact numbers are hard to pin down because it's invisible to standard screening. Millions, certainly. Anyone who's been exposed to hepatitis B but cleared the acute infection could still harbor the virus in their liver.
Il Polso
- Occult hepatitis B evades standard screening entirely, meaning millions may carry a cancer-driving infection that medicine routinely fails to see.
- Five specific pre-S mutations force liver cells through a critical division checkpoint at dangerous speed, triggering aggressive, uncontrolled proliferation.
- The mutations flood cells with excess surface protein that hijacks the Akt/mTOR growth pathway, dismantling the molecular brakes that normally prevent tumor formation.
- Lab experiments with MK2206 and rapamycin successfully halted mutation-driven cell division, restoring the arrested state that keeps cancer from advancing.
- The work now awaits clinical trials to determine whether this precisely mapped molecular intervention can protect real patients from a cancer that hides in plain sight.
Beneath the threshold of standard detection, a shadow form of hepatitis B quietly rewires the liver's most fundamental instructions for growth and restraint. Researchers in Beijing have now traced the precise molecular path by which five mutations in the virus's pre-S region overwhelm the cell's natural brakes, activating a signaling cascade that transforms regulated tissue into uncontrolled tumor. In mapping this hidden mechanism, they have also identified two existing drugs capable of interrupting it — a discovery that places precision medicine one step closer to a disease that has long refused to announce itself.
Hepatitis B carries a shadow form — occult hepatitis B infection, or OBI — that evades standard diagnostic markers while silently driving liver cancer. For years, researchers observed that mutations in the virus's pre-S region correlated with advanced disease, but the mechanism connecting viral genetics to tumor growth remained unresolved.
A Beijing research team constructed both normal and mutated versions of the virus and introduced them into cultured human liver cells. Five specific pre-S mutations — E39K, D44N, N98T, H128R, and I161T — each accelerated the G1/S cell cycle transition, the checkpoint at which cells commit to dividing. Mutated cells proliferated aggressively, far outpacing their unaltered counterparts.
Tracing the molecular sequence, the team found that these mutations caused cells to overproduce large hepatitis B surface protein, which in turn activated the Akt/mTOR signaling pathway. That activation flooded cells with Cyclin D1, CDK4, and CDK6 — proteins that accelerate division — while the normal restraints on replication disappeared entirely.
The researchers then tested whether existing compounds could interrupt this cascade. Both MK2206, an Akt inhibitor, and rapamycin, which blocks mTOR, successfully arrested the malignant proliferation in culture, returning cells to a non-dividing state. Published in Genes & Diseases, the findings chart a clear line from viral mutation to cancer mechanism to candidate treatment — though clinical trials in actual patients will be required before laboratory promise becomes medical reality.
Hepatitis B has a shadow form that most screening tests miss entirely. Called occult hepatitis B infection, or OBI, it lurks in the liver without triggering the standard markers doctors look for—yet it drives the development of hepatocellular carcinoma with relentless efficiency. For years, researchers knew that certain mutations in the virus's pre-S region correlated with advanced liver disease, but the actual mechanism by which these genetic variants hijacked the body's own cellular machinery to fuel tumor growth remained a mystery.
A team from Beijing's National Center of Gerontology and Peking Union Medical College set out to crack that mystery. They constructed laboratory versions of the hepatitis B virus—both normal and mutated—and introduced them into human liver cancer cells grown in culture. What they found was precise and troubling: five specific mutations in the pre-S region, labeled E39K, D44N, N98T, H128R, and I161T, all accelerated the cell cycle's critical G1/S transition, the checkpoint where cells commit to dividing. The mutated virus-infected cells began proliferating aggressively, far outpacing their normal counterparts.
The researchers then traced the molecular dominos that fell in sequence. The mutations caused infected cells to overproduce a protein called large hepatitis B surface protein, or LHBs. This excess LHBs activated a signaling pathway known as Akt/mTOR, a cellular communication system that normally helps regulate growth. Once activated, this pathway flooded the cells with Cyclin D1 and related proteins—CDK4 and CDK6—that act as accelerators for cell division. The normal brakes that keep cells from dividing uncontrollably simply vanished. The infected liver cells entered a state of unregulated proliferation, the hallmark of cancer.
But the researchers didn't stop at diagnosis. They tested whether existing drugs could interrupt this cascade. Two compounds showed remarkable promise: MK2206, an inhibitor of the Akt protein, and rapamycin, which blocks mTOR. When either drug was added to the mutated hepatoma cells in culture, the malignant growth stopped. The cells arrested back in the G0/G1 phase, unable to progress toward division. By chemically blocking the Akt/mTOR axis, the researchers had essentially stripped the mutated cells of their oncogenic advantage, restoring the liver cells' capacity to resist uncontrolled replication.
The findings, published in the journal Genes & Diseases, map a clear path from viral mutation to cancer mechanism to potential treatment. Yet the researchers were careful to note that laboratory success does not automatically translate to human benefit. The next phase requires clinical trials—real patients with occult hepatitis B infection, treated with these targeted kinase inhibitors, to determine whether the promise observed in cultured cells can be realized in living bodies. What the work does establish is that precision medicine approaches targeting the Akt/mTOR pathway may offer a new generation of treatments for hepatocellular carcinoma driven by these occult viral mutations, a disease that has long evaded both detection and effective intervention.
Citazioni salienti
These mutations aggressively up-regulate the expression of the large hepatitis B surface protein, which subsequently triggers a massive activation of the Akt/mTOR signaling cascade— Research team, National Center of Gerontology and Peking Union Medical College
Additional clinical studies are necessary to translate these targeted interventions into human therapies— Researchers, Genes & Diseases publication
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗
Health & Medicine